Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
May 2023
Litifilimab (BIIB059), a Promising Investigational Drug for Cutaneous Lupus Erythematosus
Expert Opin Investig Drugs 2023;15:1-9 doi 10.1080/13543784.2023.2212154
Cho, et al. discuss the current challenges in the approval of CLE drugs and suggest outcome measures that could streamline the process. They also discuss the pharmacodynamics of litifilimab and the current status of clinical trials.
December 2022
Low-dose Interleukin-2 Therapy in Active Systemic Lupus Erythematosus (LUPIL-2): A Multicentre, Double-blind, Randomised and Placebo-controlled Phase II Trial
Ann Rheum Dis. 2022;81:1685–1694
Phase II proof-of-concept trial confirms that low-dose IL-2 therapy can safely and selectively expand the Treg population, and is capable of reducing disease activity in patients with SLE.